AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9817289 — intervention group
Group type: COMPARATOR
Intervention: No additional tool (nothing else)
Number of subjects: 128
Study 7650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg
Number of subjects: 6
Study 7650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 2 mg
Number of subjects: 6
Study 7650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 4 mg
Number of subjects: 6
Study 7650223 — intervention group
Group type: EXPERIMENTAL
Intervention: Draflazine 6 mg
Number of subjects: 6
Study 7650223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2566286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (15 micrograms/kg/h during the first 2 h, 30 micrograms/kg/h from the 3rd to the 12th h)
Number of subjects: 40
Study 2566286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2566286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 40
Study 795440 — intervention group
Group type: EXPERIMENTAL
Intervention: D-oxazepam hemisuccinate sodium salt (100 mg i.m.)
Number of subjects: 34
Study 795440 — intervention group
Group type: COMPARATOR
Intervention: Racemic form of D-oxazepam (100 mg i.m.)
Number of subjects: 34
Study 7012246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular amikacin (5 mg via Rickham reservoir)
Number of subjects: 0
Study 7012246 — intervention group
Group type: COMPARATOR
Intervention: Intraventricular therapy
Number of subjects: 0
Study 31126315 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 140
Study 31126315 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 140
Study 31126315 — intervention group
Group type: COMPARATOR
Intervention: PEG 4000
Number of subjects: 140
Study 31126315 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 140
Study 28831839 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized sound therapy
Number of subjects: 18
Study 28831839 — intervention group
Group type: COMPARATOR
Intervention: Broadband noise therapy
Number of subjects: 18
Study 27548054 — intervention group
Group type: EXPERIMENTAL
Intervention: LR3 plus KI3 acupoints
Number of subjects: 57
Study 27548054 — intervention group
Group type: EXPERIMENTAL
Intervention: LR3 plus sham acupoint
Number of subjects: 57
Study 27548054 — intervention group
Group type: COMPARATOR
Intervention: LR3 alone
Number of subjects: 57
Study 24253956 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoaxial locking technique
Number of subjects: 124
Study 24253956 — intervention group
Group type: COMPARATOR
Intervention: Polyaxial locking technique
Number of subjects: 124
Study 21990511 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus self‐selected music via overhead stereo system
Number of subjects: 48
Study 21990511 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 19893125 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal electrophoresis of vanadium
Number of subjects: 67
Study 17950088 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (<=30 years)
Number of subjects: 315
Study 17950088 — intervention group
Group type: COMPARATOR
Intervention: Older patients (>30 years)
Number of subjects: 315
Study 15096905 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg per day
Number of subjects: 65
Study 11966786 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide-cartilage complex (MCC) healing ointment
Number of subjects: 19
Study 11966786 — intervention group
Group type: COMPARATOR
Intervention: Aquaphor ointment
Number of subjects: 19
Study 9816562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity Day simulation activity
Number of subjects: 77
Study 9816562 — intervention group
Group type: COMPARATOR
Intervention: Presimulation attitude scores
Number of subjects: 77
Study 7666251 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bread-based diet (daily intake 274 g starch, 2.4 g enzyme-resistant starch, 14.4 g total dietary fiber)
Number of subjects: 9
Study 7666251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran-based diet (daily intake 243 g starch, 2.7 g enzyme-resistant starch, 40.2 g total dietary fiber)
Number of subjects: 9
Study 7666251 — intervention group
Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 9
Study 7666251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat bran-based diet
Number of subjects: 9
Study 2711724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Prostaglandin E2 (PGE2) gel application within 6 hours after PROM
Number of subjects: 416
Study 2711724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical Prostaglandin E2 (PGE2) gel application within 7-12 hours after PROM
Number of subjects: 416
Study 2711724 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion after 12 hours of waiting
Number of subjects: 416
Study 2711724 — intervention group
Group type: COMPARATOR
Intervention: Waiting 12 hours for spontaneous labor
Number of subjects: 416
Study 798636 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated cholera vaccine
Number of subjects: 998
Study 798636 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially purified toxoid preparation
Number of subjects: 998
Study 798636 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐cell heat‐killed cholera vaccine
Number of subjects: 998
Study 798636 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐cell heat‐killed El Tor vaccine
Number of subjects: 998
Study 798636 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic syringe
Number of subjects: 998
Study 798636 — intervention group
Group type: COMPARATOR
Intervention: Jet injector
Number of subjects: 998
Study 31709823 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 31709823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31449758 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EXE); 12 weeks, 4 days/week, 40-60 minutes/day at >70% HRpeak
Number of subjects: 35
Study 31449758 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL); maintaining usual activity
Number of subjects: 35
Study 29078762 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment program for high fracture risk women in the intervention group, based on screening program including FRAX, DXA, and IVA.
Number of subjects: 0
Study 29078762 — intervention group
Group type: COMPARATOR
Intervention: Usual care for the control group, with screening at the end of the trial.
Number of subjects: 0
Study 26630467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily for 14 days postoperatively
Number of subjects: 170
Study 26630467 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 170
Study 26630467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Aspirin and Control)
Number of subjects: 170
Study 23899116 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive pen (intervention group)
Number of subjects: 125
Study 23899116 — intervention group
Group type: COMPARATOR
Intervention: No pen (control group)
Number of subjects: 125
Study 21237715 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E
Number of subjects: 894
Study 21237715 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 894
Study 19475459 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prescribing alerts alone
Number of subjects: 14
Study 19475459 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized prescribing alerts plus group educational sessions
Number of subjects: 14
Study 19475459 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14
Study 19475459 — intervention group
Group type: COMPARATOR
Intervention: Comparison of alert-group to usual care
Number of subjects: 14
Study 19475459 — intervention group
Group type: COMPARATOR
Intervention: Comparison of alert-plus-education group to usual care
Number of subjects: 14
Study 19475459 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of alert-group to alert-plus-education group
Number of subjects: 14
Study 17325089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin/sulbactam for 48 hours followed by oral amoxicillin/clavulanate for 7 days
Number of subjects: 60
Study 17325089 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin for 48 hours followed by oral clindamycin for 7 days
Number of subjects: 60
Study 15361375 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate with folate supplementation
Number of subjects: 411
Study 15361375 — intervention group
Group type: COMPARATOR
Intervention: Low dose methotrexate (non-adherent group)
Number of subjects: 411
Study 15361375 — intervention group
Group type: COMPARATOR
Intervention: High dose methotrexate (non-adherent group)
Number of subjects: 411
Study 15361375 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to guidelines
Number of subjects: 411
Study 12047964 — intervention group
Group type: EXPERIMENTAL
Intervention: de Gramont regimen (folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days 1 and 2, repeated every 14 days)
Number of subjects: 905
Study 12047964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokich regimen (protracted venous infusion of fluorouracil 300 mg/m(2) daily)
Number of subjects: 905
Study 12047964 — intervention group
Group type: EXPERIMENTAL
Intervention: raltitrexed (3 mg/m(2) intravenously every 21 days)
Number of subjects: 905
Study 12047964 — intervention group
Group type: COMPARATOR
Intervention: raltitrexed
Number of subjects: 905
Study 12047964 — intervention group
Group type: COMPARATOR
Intervention: de Gramont versus Lokich
Number of subjects: 905
Study 12047964 — intervention group
Group type: COMPARATOR
Intervention: de Gramont versus raltitrexed
Number of subjects: 905
Study 9474447 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 79
Study 9474447 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ECT (2.5 x threshold)
Number of subjects: 79
Study 9474447 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 79
Study 9474447 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 79
Study 7699188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-energy nutrition supplement consumed at a maximum of 30% of estimated daily energy requirements
Number of subjects: 19
Study 7699188 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-energy nutrition supplement
Number of subjects: 19
Study 2494948 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC + HCFU
Number of subjects: 69
Study 2494948 — intervention group
Group type: COMPARATOR
Intervention: MMC only
Number of subjects: 69
Study 403767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plan at M.D. Anderson Hospital and Tumor Institute (Group B)
Number of subjects: 101
Study 403767 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy plan at University of Mississippi Medical Center (Group A)
Number of subjects: 101
Study 30665989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 29058112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 0.25 g kg‐1 FFM
Number of subjects: 10
Study 29058112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 0.5 g kg‐1 FFM
Number of subjects: 10
Study 29058112 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine 0.9 g kg‐1 FFM
Number of subjects: 10
Study 29058112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25333309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic livers
Number of subjects: 19
Study 25333309 — intervention group
Group type: COMPARATOR
Intervention: Noncirrhotic livers
Number of subjects: 19
Study 23948846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power pain threshold ultrasound (HPPTUS) technique
Number of subjects: 41
Study 23948846 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound technique
Number of subjects: 41
Study 22166329 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiopsy parameters including PSA, DRE, TRUS findings, and prostate volume
Number of subjects: 19950
Study 22166329 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer
Number of subjects: 19950
Study 22166329 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate risk assessment
Number of subjects: 19950
Study 22166329 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of prostate cancer
Number of subjects: 19950
Study 19680682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-rest for 56 days
Number of subjects: 10
Study 19680682 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-chain simulated resistance exercises targeting lower-limb antigravity extensor muscles
Number of subjects: 10
Study 17349882 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/day of atorvastatin
Number of subjects: 56
Study 17349882 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/day of ezetimibe plus 10 mg/day of atorvastatin
Number of subjects: 56
Study 15292365 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 microg/hr)
Number of subjects: 4
Study 15292365 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 4
Study 14564912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (HC; 65 E% carbohydrates, 20 E% fat, 15 E% protein)
Number of subjects: 7
Study 14564912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal (HF; 40 E% carbohydrates, 45 E% fat, 15 E% protein)
Number of subjects: 7
Study 14564912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric meals every four hours
Number of subjects: 7
Study 9560042 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow Driver (IFD)
Number of subjects: 20
Study 9560042 — intervention group
Group type: COMPARATOR
Intervention: Single prong nasal CPAP
Number of subjects: 20
Study 8249558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70% nitrous oxide in oxygen and fentanyl)
Number of subjects: 42
Study 8249558 — intervention group
Group type: COMPARATOR
Intervention: Air (isoflurane in air/oxygen and fentanyl)
Number of subjects: 42
Study 3622197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) group, 0.71 ± 0.12 g X kg‐1 X day‐1 protein for 4.5 ± 1 months
Number of subjects: 16
Study 3622197 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NPD) group, 1.44 ± 0.12 g X kg‐1 X day‐1 protein for 11.7 ± 7 months
Number of subjects: 16
Study 29338326 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 0
Study 29338326 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CFAEs
Number of subjects: 0
Study 29338326 — intervention group
Group type: COMPARATOR
Intervention: PVI
Number of subjects: 0
Study 27009295 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 30
Study 27009295 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 30
Study 24243080 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 60
Study 24243080 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA(®) 5% cream
Number of subjects: 60
Study 24243080 — intervention group
Group type: COMPARATOR
Intervention: Vaseline (Control)
Number of subjects: 60
Study 22417316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT®)
Number of subjects: 285
Study 22417316 — intervention group
Group type: COMPARATOR
Intervention: Social-support group meetings (SS)
Number of subjects: 285
Study 19815042 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplements
Number of subjects: 99
Study 19815042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 17629133 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0
Study 17629133 — intervention group
Group type: COMPARATOR
Intervention: Conservative bowel management
Number of subjects: 0
Study 16204662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) guided therapy
Number of subjects: 433
Study 16204662 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment alone (Control)
Number of subjects: 433
Study 11936390 — intervention group
Group type: EXPERIMENTAL
Intervention: Laster 'shark‐fin' osteotome
Number of subjects: 10
Study 11936390 — intervention group
Group type: COMPARATOR
Intervention: Obwegeser osteotome
Number of subjects: 10
Study 10396888 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary psychoeducational family group intervention (7 weekly, 2-hour sessions)
Number of subjects: 94
Study 10396888 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 94
Study 7742756 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, and Fractionated Total Body Irradiation
Number of subjects: 56
Study 1539456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis DTP vaccine containing 12.5 micrograms (AC-12.5)
Number of subjects: 111
Study 1539456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis DTP vaccine containing 25 micrograms (AC-25)
Number of subjects: 111
Study 1539456 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell DTP (WC-DTP)
Number of subjects: 111
Study 1539456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccines (AC-12.5 and AC-25)
Number of subjects: 111
Study 1539456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine (AC-12.5)
Number of subjects: 111
Study 3104512 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic i.v. nitroglycerin at a dose of 0.7 microgram/kg‐1/min‐1
Number of subjects: 0
Study 3104512 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia induced by fentanyl, flunitrazepam and pancuronium maintained with N20 and volatile anesthetics
Number of subjects: 0
Study 31557492 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-5190457 (GHS-R1a inverse agonist)
Number of subjects: 0
Study 31557492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30290622 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow induction of light general anesthesia and tracheal intubation (group M)
Number of subjects: 30
Study 30290622 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask light general anesthesia (group H)
Number of subjects: 30
Study 27132086 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on dTMS (n=7)
Number of subjects: 14
Study 27132086 — intervention group
Group type: COMPARATOR
Intervention: Standard abortive or preventive antimigraine treatment (n=7)
Number of subjects: 14
Study 26154456 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLB)
Number of subjects: 25
Study 26154456 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (CLB)
Number of subjects: 25
Study 26399269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 0
Study 26399269 — intervention group
Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 0
Study 21601822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 56
Study 21601822 — intervention group
Group type: COMPARATOR
Intervention: Suture fixation
Number of subjects: 56
Study 18773960 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA/MMF
Number of subjects: 200
Study 18773960 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA/SRL
Number of subjects: 200
Study 18773960 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 200
Study 18773960 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 200
Study 17138783 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin training
Number of subjects: 140
Study 17138783 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity mannequin training
Number of subjects: 140
Study 12648884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol
Number of subjects: 152
Study 12648884 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol
Number of subjects: 152
Study 12648884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 10884878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g)
Number of subjects: 780
Study 10884878 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (160 mg trimethoprim, 800 mg sulfamethoxazole)
Number of subjects: 780
Study 7780671 — intervention group
Group type: EXPERIMENTAL
Intervention: Coils (Timor and Moon Tiger containing 0.15% W/W of esbiothrin)
Number of subjects: 1029
Study 7780671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mats (ARS MATS containing d-allethrin and Moon Tiger with S biothrin and diethyl-toluamide)
Number of subjects: 1029
Study 7780671 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1029
Study 7780671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mats (ARS MATS)
Number of subjects: 1029
Study 2185962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg, orally, twice daily for 4 weeks)
Number of subjects: 71
Study 2185962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally, twice daily for 4 weeks)
Number of subjects: 71
Study 2185962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 71
Study 2185962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 6996660 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral practolol 200 mg twice daily
Number of subjects: 55
Study 6996660 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study 31712735 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 early symptoms/sensations combined with 7 background factors
Number of subjects: 506
Study 31712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptors only
Number of subjects: 506
Study 31712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Background predictors only
Number of subjects: 506